CALLIDITAS THERAPEUTICS AB

Analyst Reco. Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Real-time Estimate Cboe BZX Other stock markets 07:45:23 03/06/2024 pm IST			5-day change	1st Jan Change
39.72 ^USD	-0.68%		+4.35%	+53.82%

31/05	Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39	MT
31/05	Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39	31/05	MT
HC Wainwright Downgrades Calliditas Therapeutics to Neutral From Buy, Cuts Price Target to $39 From $45	28/05	MT
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55	28/05	MT
HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating	24/05	MT
Guggenheim Adjusts Calliditas Therapeutics' Price Target to $18 From $21, Keeps Neutral Rating	18/23/18	MT
HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target	20/23/20	MT
Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target	01/23/01	MT
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates Buy Rating	20/21/20	MT
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy Rating	20/21/20	MT
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company...	07/21/07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer